Invention Grant
![1-(4-pyrimidinyl)-1H-pyrrolo[3,2-c]pyridine derivatives as NIK inhibitors](/docs/US/2018-06-26/US10005773B2/abs.jpg.600x600.jpg)
- Patent Title: 1-(4-pyrimidinyl)-1H-pyrrolo[3,2-c]pyridine derivatives as NIK inhibitors
-
Application No.: US15024603Application Date: 2014-09-25
-
Publication No.: US10005773B2Publication Date: 2018-06-26
- Inventor: George Hynd , Patrizia Tisselli , David Edward Clark , Janusz Jozef Kulagowski , Calum MacLeod , Samuel Edward Mann , Terry Aaron Panchal , Stephen Colin Price , John Gary Montana
- Applicant: Janssen Pharmaceutica NV
- Applicant Address: BE Beerse
- Assignee: Janssen Pharmaceutica NV
- Current Assignee: Janssen Pharmaceutica NV
- Current Assignee Address: BE Beerse
- Priority: EP13186139 20130926; EP14176121 20140708
- International Application: PCT/EP2014/070484 WO 20140925
- International Announcement: WO2015/044267 WO 20150402
- Main IPC: A61K31/506
- IPC: A61K31/506 ; C07D471/04
![1-(4-pyrimidinyl)-1H-pyrrolo[3,2-c]pyridine derivatives as NIK inhibitors](/abs-image/US/2018/06/26/US10005773B2/abs.jpg.150x150.jpg)
Abstract:
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-κB-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
Public/Granted literature
- US20160257679A1 NEW 1-(4-PYRIMIDINYL)-1H-PYRROLO[3,2-c]PYRIDINE DERIVATIVES AS NIK INHIBITORS Public/Granted day:2016-09-08
Information query
IPC分类:
